Company News

bioMérieux announces an investment of more than one million Swiss Francs in Plair, a scale-up company offering a breakthrough solution for real-time microbial detection and air sampling. 

Respiratory symptoms send millions of people to emergency departments (EDs) every year. For clinicians, sorting through those symptoms quickly isn’t easy. For patients, that uncertainty can be stressful: long waits, unclear answers, and sometimes unnecessary treatments, including antibiotics that won’t help viral infections.

Global health leaders unite to unlock the value of diagnostics in the fight against antimicrobial resistance.

As 2026 begins, bioMérieux proudly continues our tradition of looking into the next twelve months and analyzing how key food safety trends will influence the food supply chain and our partners’ operations. The three identified trends for 2026 will continue to develop and inform food safety and quality standards — standards that we at bioMérieux are proud to help pioneer and contribute to.

bioMérieux confirms its ethical commitment to clinical research through a Bioethics Charter that guarantees transparency, accountability, and respect for human dignity. In particular, it aims to protect research participants when collecting and using biological samples and personal data.